Cancer Chemotherapy and Pharmacology

, Volume 76, Issue 3, pp 439–445 | Cite as

Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate

  • Roberto Petrioli
  • Edoardo Francini
  • Letizia Laera
  • Anna Ida Fiaschi
  • Roberto Ponchietti
  • Giandomenico Roviello
Review Article


Abiraterone acetate is a novel irreversible inhibitor of CYP17 that was recently approved for men with post-chemotherapy or chemo-naive castration-resistant prostate cancer. Unfortunately, this agent is not curative, and patients often ultimately develop resistance. However, men who progress after treatment with this new hormonal agent may be considered for another line of chemotherapy-based treatment. In 2004, docetaxel (D) and prednisone were found to improve survival compared with older regimens. More recently, cabazitaxel (C), a novel taxane chemotherapy, has been found to prolong survival in patients who exhibit disease progression during or after D chemotherapy. Here, we review the first clinical studies in which castration-resistant prostate cancer patients received chemotherapy with D or C after progression during abiraterone acetate treatment.


Abiraterone acetate Docetaxel Cabazitaxel Prostate cancer 


  1. 1.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ et al (2011) Abiraterone increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRefPubMedGoogle Scholar
  3. 3.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154CrossRefPubMedGoogle Scholar
  4. 4.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) IMPACT study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422CrossRefPubMedGoogle Scholar
  5. 5.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O (2013) ALSYMPCA investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223CrossRefPubMedGoogle Scholar
  6. 6.
    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE (2015) COU-AA-302 investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160CrossRefPubMedGoogle Scholar
  8. 8.
    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) The PREVAIL investigators. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med 371:424–433PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Francini E, Petrioli R, Roviello G (2014) No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 10:1135–1140CrossRefGoogle Scholar
  10. 10.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefPubMedGoogle Scholar
  11. 11.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520CrossRefPubMedGoogle Scholar
  12. 12.
    Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick Cassidy A, Olmos D, Attard G, de Bono J (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23(11):2943–2947CrossRefPubMedGoogle Scholar
  13. 13.
    Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN (2014) A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74(15):1544–1550CrossRefPubMedGoogle Scholar
  14. 14.
    Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES (2014) Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 74(13):1278–1285CrossRefPubMedGoogle Scholar
  15. 15.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y (2014) Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. doi:10.1016/j.eururo.2014.04.015 PubMedGoogle Scholar
  16. 16.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G (2013) Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66(3):459–465. doi:10.1016/j.eururo.2013.11.044 CrossRefPubMedGoogle Scholar
  17. 17.
    Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H (2014) CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer. 20 Sep 2014Google Scholar
  18. 18.
    Caffo O, De Giorgi U, Fratino L et al (2014) Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian Multicentre Study. Eur Urol. doi:10.1016/j.eururo.2014.10.014 Google Scholar
  19. 19.
    Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, Rembert D, Yap M, Schnadig I (2015) Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices. Clin Genitourin Cancer. doi:10.1016/j.clgc.2014.12.019 Google Scholar
  20. 20.
    Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI (2013) COU-AA-301 investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49(17):3648–3657CrossRefPubMedGoogle Scholar
  22. 22.
    Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF (2008) TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749–1753CrossRefPubMedGoogle Scholar
  23. 23.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMedGoogle Scholar
  24. 24.
    Oudard S, de Bono J, Ozguroglu M, Hansen S, Machiels J, Kocak I et al (2012) Impact of cabazitaxel (Cbz) + prednisone (P; CbzP) on overall survival (OS) at 2 years and in patients (pts) with aggressive disease: post hoc analyses of TROPIC trial. In: Presented at European Society for Medical Oncology Vienna, Austria 28 Sept–2 Oct 2012Google Scholar
  25. 25.
    Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I et al (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402–2408PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66(4):646–652CrossRefPubMedGoogle Scholar
  27. 27.
    Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH (2009) Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 69:1579–1585CrossRefPubMedGoogle Scholar
  28. 28.
    Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992–8002PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H (2009) Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69:8386–8394PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74(8):2270–2282PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ (2015) Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2015.01.004 Google Scholar
  32. 32.
    Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ (2014) Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 12(5):e167–e172CrossRefPubMedGoogle Scholar
  33. 33.
    Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E (2015) Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. Med Oncol 32(3):52CrossRefPubMedGoogle Scholar
  34. 34.
    Buonerba C, Pond GR, Sonpavde G et al (2013) Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol 9:889–897CrossRefPubMedGoogle Scholar
  35. 35.
    van Soest RJ, de Morree ES, Shen L et al (2014) Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol 66:330–336CrossRefPubMedGoogle Scholar
  36. 36.
    National Institutes of Health (2014) NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy, updated June 1, 2014. Available at: newsfromnci/2013/E3805. Accessed 17 Jan 2015
  37. 37.
    Roviello G et al (2015) The third line of treatment for metastatic prostate cancer patients: option or strategy? Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2015.04.010 Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Roberto Petrioli
    • 1
  • Edoardo Francini
    • 2
  • Letizia Laera
    • 1
  • Anna Ida Fiaschi
    • 3
  • Roberto Ponchietti
    • 4
  • Giandomenico Roviello
    • 1
  1. 1.Medical Oncology Unit, Department of Medicine, Surgery and NeurosciencesUniversity of SienaSienaItaly
  2. 2.Medical Oncology Unit, Policlinico Umberto I HospitalUniversity of RomeRomeItaly
  3. 3.Pharmacology UnitUniversity of SienaSienaItaly
  4. 4.Urological and Andrological Unit, Santa Maria alle Scotte HospitalUniversity of SienaSienaItaly

Personalised recommendations